NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Developing Innovative Drug Candidates to Treat Cancer, Alzheimer’s Disease

June 20, 2019 13:24:16

INmune Bio (NASDAQ: INMB), a diversified clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to combat disease, is currently developing drug candidates INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease. An article further discussing the company reads, “XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer’s disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction — the cause of dementia in Alzheimer’s. A phase I clinical trial in patients with Alzheimer’s disease, supported by the Alzheimer’s Association grant, is expected to be initiated in the summer of 2019. . . . Upcoming catalysts for INmune Bio include advancements in several clinical trials featuring INB03 and INKmune — both of which are focused on ‘taking the brakes off’ the body’s innate immune system to become a powerful weapon in the fight against cancer. INB03 is a checkpoint inhibitor that targets cells resistant to immunotherapy to instead become therapeutically effective; INKmune primes a patient’s own natural killer cells to move from a resting state to an active state to attack and eliminate residual disease (lingering cancer cells) after cancer therapy.”

To view the full article, visit http://nnw.fm/M19Hy

About INmune Bio Inc.

INmune Bio Inc. (NASDAQ: INMB) is a publicly traded, clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that re-engineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.INmuneBio.com.

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://nnw.fm/INMB

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com